Dr. John Cush RheumNow
6 years 9 months ago
When patients come to clinic with a list of questions, its best to address the whole list at the start, and not the end, of the visit. Now your putting patient priorities ahead of your MD priorities - isnt that what your paid to do?
Gilead has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis (RA).
Dr. John Cush RheumNow
6 years 9 months ago
FDA has approved a new sleep drug, Dayvigo, 5 mg and 10 mg, based on two late-stage placeboe controlled studies for insomnia. Use for 1-6 months, to be classified as a controlled substance because it can be addictive and has the potential to be abused https://t.co/e2ZVWm39tN
Millennial physicians comprise a wider, diverse population compared to prior generations, including an ever-increasing female physician community. It is estimated that by 2025, 75% of the work force will be millennials.1 This generation grew up in an era of participation trophies and structured childhood schedules, all while watching their predecessors sacrifice work/life balance due to persistent slashing of reimbursement. All of this sets the
Dr. John Cush RheumNow
6 years 9 months ago
Gabapentin and baclofen use, misuse, toxicity, & suicide attempts increased in the United States since 2013. Gabapentin use increased 72% and baclofen increased 37% from 2014 to 2017. https://t.co/50IY7WcFXq
Dr. John Cush RheumNow
6 years 9 months ago
COAST-X trial: Ixekizumab was superior to placebo for improving signs and symptoms in patients with non-radiographic axial spondyloarthritis at weeks 16 and 52. ASAS40 at week 52 IXE q4W 30% vs. IXE Q2W 31% vs PBO 13%, p=0·0037 https://t.co/GrQnakvor1
Dr. Jack Cush reviews the news from the past week on RheumNow.com, just in time for Christmas!
Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.
Adam Kilian MD KilianMD
6 years 9 months ago
#Doctors on the road:
Which specialties are caught speeding most often?...
Hilarious and awesome study, and a great interactive graphic (click the link!) bravo 👏🏻
The need for speed: observational study of physician driving behaviors | The BMJ https://t.co/wmBBOjSCct
Leonard Calabrese LCalabreseDO
6 years 9 months ago
read my take on ACR update on BIOMARKERS @CreakyJoints @ArthritisFdn https://t.co/0HjN7jeIQh
Ali Duarte, MD AliDuarteMD
6 years 9 months ago
So many new treatments on the horizon: voclosporin, anifrolumab, belimumab for LN. The year of the wolf 🐺
#Lupus https://t.co/uDzIzU0pvK
Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by trial of belimumab for the treatment of active lupus nephritis in adult patients.
The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.
